Among the many complexities of cancer, two challenges stand out: the inherent heterogeneity of tumors and their rapid evolution, both with time and in response to treatments. CellsBin’s technology can profile the ever-changing landscape of cancer cells with precision, tracing their journey through time and treatments. This not only arms physicians with invaluable insights but paves the way for truly adaptive cancer care, tailored for each individual. Direct cell analysis trumps the limited genomic traces that float around in our bloodstream. Harnessing this, CellsBin has developed a technique that spots single circulating tumor cells with unparalleled accuracy, minimizing false positives. The synergy of these three revolutions amplifies our capabilities, ensuring that CellsBin not only detect cancer cells but truly understand their intricate narratives.

  1. Generative AI: By simulating complex biological scenarios, Generative AI helps us predict and understand the myriad ways cancer cells evolve and interact within the body. This foresight is invaluable in deciphering early-stage cancer signals, setting the stage for proactive intervention.
  2. Monolithic Multi-Stack Nanofabrication: Through the innovations in monolithic multi-stack nanofabrication, we’re now able to manipulate and construct intricate biological sensors at the molecular level. This precision ensures that we can detect even the faintest presence of circulating tumor cells, capturing signals that would have been missed by older technologies.
  3. Ultra-High Sensitivity Imaging: Ultra-high sensitivity, paired with low power requirements, means we can now visualize cellular structures and changes with unprecedented clarity. CellsBin has harnessed this technology, adapting it to peer into the microscopic world of blood cells, providing a window into the earliest stages of cancer.

In the journey of life, nothing is more invaluable than time. Especially for those touched by cancer, early detection is not just about survival; it’s about thriving. CellsBin is a Medical Technology start-up company that is setting a new paradigm in cell-analysis with its patentable VEGA platform, marking a monumental advancement beyond the era of flow cytometry since the 1970s. Integrating novel photonics, microfluidics and AI, VEGA platforms distinguishes itself by detecting and isolating cells that are 1000 times rarer than what is possible with traditional flow cytometry, offering unmatched precision and scale. This leap forward facilitates groundbreaking applications in precision oncology, immunotherapy, regenerative medicine, and drug discovery.

Located in New Haven, CT, blocks away from the Yale campus, CellsBin is led by veteran founders with extensive expertise in photonics, molecular biology, and AI. Launched in Q4 2023, their debut, VEGA 1.2, is already uncovering insights previously beyond reach, in partnership with some of the world’s most prestigious cancer research and academic institutions. Rouzbeh Yassini is the board member to CellsBin Inc.